<SEC-DOCUMENT>0001193125-13-335754.txt : 20130815
<SEC-HEADER>0001193125-13-335754.hdr.sgml : 20130815
<ACCEPTANCE-DATETIME>20130815091706
ACCESSION NUMBER:		0001193125-13-335754
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130815
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130815
DATE AS OF CHANGE:		20130815

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AxoGen, Inc.
		CENTRAL INDEX KEY:			0000805928
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				411301878
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36046
		FILM NUMBER:		131040763

	BUSINESS ADDRESS:	
		STREET 1:		13859 PROGRESS BLVD.
		STREET 2:		SUITE 100
		CITY:			ALACHUA
		STATE:			FL
		ZIP:			32615
		BUSINESS PHONE:		(386) 462-6817

	MAIL ADDRESS:	
		STREET 1:		13859 PROGRESS BLVD.
		STREET 2:		SUITE 100
		CITY:			ALACHUA
		STATE:			FL
		ZIP:			32615

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LECTEC CORP /MN/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d585305d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Form 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Current Report </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>of the Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported):&nbsp;August&nbsp;15, 2013 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>AXOGEN, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Minnesota</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1-36046</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>41-1301878</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13859 Progress Boulevard, Suite 100,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Alachua, Florida</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>32615</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Cope)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(386) 462-6800 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address if changed since last report,) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01 Other Information </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;15, 2013, AxoGen, Inc. (the &#147;Company&#148;) issued a press release announcing the completion of the underwritten offering of 6,000,000 shares of common stock at a price to the public
of $3.00 per share (before underwriting discount) and the filing of its quarterly report on Form 10-Q for the second quarter of 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
connection with the offering, the Company received gross proceeds of approximately $18 million, excluding the underwriters&#146; over-allotment option and deductions for underwriting discounts and commissions and estimated expenses. JMP Securities
LLC acted as the sole book-running manager in the offering and Ladenburg Thalmann&nbsp;&amp; Co. Inc., acted as co-manager. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A copy of the
press release is filed herewith as Exhibit 99.1. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:37pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit&nbsp;No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen, Inc. press release, dated August 15, 2013.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">AXOGEN, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: August 15, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Gregory G. Freitag</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gregory G. Freitag</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:37pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit&nbsp;No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen, Inc. press release, dated August 15, 2013.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d585305dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g585305g79a08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AxoGen, Inc. Closes $18 Million Offering and Moves to NASDAQ </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Files second quarter 2013 quarterly report on Form 10-Q </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ALACHUA, FL &#150; August&nbsp;15, 2013 &#150; AxoGen, Inc. (NASDAQ: AXGN), a leading regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral
nerve reconstruction and regeneration, today announced the closing of an underwritten offering of 6,000,000 shares of its common stock at a price to the public of $3.00 per share. The Company received gross proceeds of approximately $18 million,
excluding the underwriters&#146; over-allotment option and deductions for underwriting discounts and commissions and estimated expenses. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen also announced that it has filed its quarterly report on Form 10-Q for the second quarter of 2013 with the Securities and Exchange Commission
(SEC). Second quarter 2013 highlights included: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenues increased 42.2% from 2Q 2012 to $2.86 million </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross profit increased 47.6% from 2Q 2012 to $2.23 million </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross profit margin at 77.9%, up 2.8% from 2Q 2012 </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating Loss increased 38.2% from 2Q 2012 to $2.19 million </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Received CE Mark and Health Canada Approval for AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
Nerve Connector </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Karen Zaderej, Chief Executive Officer of AxoGen, said, &#147;I am delighted with the many milestones
AxoGen has achieved this year. Our move to NASDAQ places AxoGen among the leading innovative growth companies; provides more efficient trading for our shareholders; and increases our visibility to institutional shareholders. The successful closing
of this $18 million stock offering provides additional validation of the peripheral nerve repair market as a growth segment. In addition, our strong revenue performance to date demonstrates the traction we are gaining in that market. &#148;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen will use the net proceeds from the offering to expand product commercialization and marketing efforts for its
portfolio of peripheral nerve repair products (Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector); to further develop its product pipeline; and for general working capital purposes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A registration statement relating to these securities has been declared effective by the SEC. The registration statement may be accessed through the SEC&#146;s website at <U>www.sec.gov</U>.&nbsp;JMP
Securities LLC is acted as the sole book-running manager in the offering and Ladenburg Thalmann&nbsp;&amp; Co. Inc., acted as co-manager. Copies of the final prospectus relating to this offering may be obtained from JMP Securities LLC, 600
Montgomery Street, 10th Floor, San Francisco, California 94111, Attention: Prospectus Department, (415)&nbsp;835-8985. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About AxoGen, Inc.
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGen (NASDAQ: AXGN) is a leading regenerative medicine company dedicated to advancing the science and
commercialization of peripheral nerve repair solutions. The Company&#146;s innovative approach to regenerative medicine has resulted in first-in-class products that we believe will define their product categories. AxoGen&#146;s products offer a full
suite of surgical nerve repair solutions including Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, the only off-the-shelf
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">
commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector, a porcine submucosa ExtraCellular Matrix (ECM) coaptation aid for tensionless repair of severed
nerves, and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured
peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">AxoGuard<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Connector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, West Lafayette, Indiana, and are distributed exclusively by AxoGen. AxoGen is the
parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen&#146;s principal executive office and operations are located in Alachua, FL. To receive email alerts directly from AxoGen, please click here
<U>www.axogeninc.com/emailalerts.html</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cautionary Statements Concerning Forward-Looking Statements </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">This Press Release contains &#147;forward-looking&#148; statements as defined in the Private Securities Litigation Reform Act of
1995. These statements are based on management&#146;s current expectations or predictions of future conditions, events or results based on various assumptions and management&#146;s estimates of trends and economic factors in the markets in which we
are active, as well as our business plans. Words such as &#147;expects&#148;, &#147;anticipates&#148;, &#147;intends&#148;, &#147;plans&#148;, &#147;believes&#148;, &#147;seeks&#148;, &#147;estimates&#148;, &#147;projects&#148;,
&#147;forecasts&#148;, &#147;continue&#148;, &#147;may&#148;, &#147;should&#148;, &#147;will&#148; variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include,
without limitation, statements regarding product commercialization and marketing efforts for its portfolio of peripheral nerve repair products, Avance<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Graft, AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve
Connector and AxoGuard<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Nerve Protector, product development, financial performance, sales growth, product
adoption, market awareness of our products, data validation and our ability to maintain the listing of our common stock on a national securities exchange. The forward-looking statements are subject to risks and uncertainties, which may cause results
to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen&#146;s business and its market, particularly those discussed in the
risk factors and cautionary statements in AxoGen&#146;s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The
forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of the
registration statement and the final prospectus. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">AxoGen, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Greg Freitag, Chief Financial Officer </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">386.462.6856 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">InvestorRelations@AxoGenInc.com
</FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g585305g79a08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g585305g79a08.jpg
M_]C_X0\!17AI9@``34T`*@````@`!P$2``,````!``$```$:``4````!````
M8@$;``4````!````:@$H``,````!``(```$Q``(````>````<@$R``(````4
M````D(=I``0````!````I````-``%N+>```G$``6XMX``"<0061O8F4@4&AO
M=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q,SHP.#HQ-2`P-3HR-SHU,@```Z`!
M``,````!``$``*`"``0````!````IJ`#``0````!````-0`````````&`0,`
M`P````$`!@```1H`!0````$```$>`1L`!0````$```$F`2@``P````$``@``
M`@$`!`````$```$N`@(`!`````$```W+`````````$@````!````2`````'_
MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`,P"@`P$B``(1
M`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]5225#K'5\?I6-ZM@WVO
MD44@^Y[O^^L;_A'HQC*4A&(LG8+9SC")E(\,8ZDIL_J&'T^@Y&78*ZQH)Y)_
M=8WZ3W+`R>N9^4T6NN9T7I[]:[;1OR;6_O4X^NUOT?\`R:Q,C.NMR#F99;D9
MY_FVN$TXX/&RH^VRYOYK'>QG^']6U57O?9:ZZQQLM?\`3L>=SC\7%:6+DXQ%
MRUEWW'^!&7_3FY&?XC*1J-QC^[\I_P"J2C_Z3Q_^&/18^3]4G/:W*NOR7DP+
M\XVN:9_XR**_^VZUOT=-QJ'-LPRZ@<EC'$UN'_$N)J_MU^]>>?ZE=I]4+WV]
M'%;B2,>Q]3"?W1#F#^SOVIG-X3"'%&<B+HQD;&K)R/,1RY."6.`E7%&<!PR]
M/<NVDDDL]U5))))*4DDDDI22222E))))*4DDDDI22222G__0]/S,NC"Q;,K(
M=MJJ;N<>_DUO\ISO:U>?9N=D9V6[,OTL=HQ@U%;!]"IG]7\__A%L?6_J!MRF
M=/8?T>.!9='>QW\TW_K=?Z3_`*XQ9.)BU.HMS\TN9@8YVNVZ/NL_-Q:/_1MG
M_G;-/E,0QX_<E\T]N_"?EC'^^XW/YI9LOLP/HQ_-^[Q1^:4OZN-%3C/M:ZP%
MM=##MLR+"16UT;O3T#GW7_\``4-?9_42<<1IBMME_P#+L/I#^S35N?\`]N6J
MQU=F10_&;E-](NI%E=+1MJJ#S_1\=O[U;=OVBS^<ML1.E]"SNI/!#748I^ED
M/$2/^`8[^<=_+_FE8XP(\<I5'S_[K])J>U(S]K'`RGUL:_XORQBULFBMF/BY
M=8<RK*]0>F\[BUU1VV;+(;OI?^;N^@NP^JN.ZCHM+GB'7EUQ']<^S_P/8N>O
MJIZQU;'Z9@",#%;Z3'-,CTVD?:LB?^%=^@8__"_37;,:UC0Q@VM:`&@<`!4^
M<RGVX0/S2/&0?FC#_)B3H?#\(][)D%&,0,8(^64ZC[LH_P!7B9+ENJ_6O+HS
MKJ,)E3JJ/876!Q)L'\Y&Q[/:QWZ-;/7.H_L[IUE[(]9WZ.@'_2.^C_F?SO\`
M87'/P13T3'S'`FS)R"UCSSZ0;9_Y]M;ZJ9RF&)]>06">"`/[WS%DY_/./ZO%
M+AE$>YDD/T8?+$?X3V_3,I^9T_'RG@!]U;7N#>)(]VV95I<OC9.=5]3J<G!L
M].[&DO\`:'2QKW-L;#P[\WWJOB?6O+JP,K[2\79>X?97%H:-KF^][_3'\WC[
M=_\`+_FTP\K.1F8549F'#^ENOCSV.(QC)Q`RQQR<?Z)]/_2>P27)_MSJ_3\%
MEV;:+LO+&['H>QK!74WG)R/2#7[K?S*?_4BJV]3^M%./3G77N91>0*G%E<&?
M<S=3LWM:]OT/>D.3F?TH;\,3?SG^KHJ7Q#'']#(37%(`"\<>GN>I[5SFM:7.
M(#0)).@`"\_ZS_C,O=>:>A4L=3NV,R[@YYM=V^R8M6U[F?Z-[OYW_0HOUO\`
MK);D?57&I:/2OZH]U.0&$P*ZOZ6&'Z6R[]'5_P`5>I?XM>CT#'OZW<P&Y[W8
M^*XCZ%5?LN=7_P`=?O8_^136H)1,9&)WB:+;A,3B)1UC(<0^KG8'^,KK&-D#
M]K5578K7AN1LK=3=4/SG^G8X[O3G>^E[*WKTIKFO:'-,M<)!'<%<=];?J5?U
M_JK<NC*HPZG8WH7O<PO>YP<XL?L:ZICMC'[??8@_6;ZW7]!KHZ#TN+\^BFIE
M^2]A<&$AM=#*L=I_39F3]-E6_97_`,(FKGN$EYEF];^O_P!7;L>_JES;FY`+
MVX[Q2YC]@FS'=9C55/QK]KO8ZM]M/_'*_P#7#ZX]3I=TP]&R?LC,O#.987UL
ML);;Z?V;=ZH=L]/]*[V)*>^27F'4_K+]=QA8F<]UF!T^YC*Z;PRG??9MW'(N
M#F6.H^T;7V44^A37Z7^E77_4CK.=UCHGVC/(?D4W64&YH#?4%9&VUU;?8Q_N
MVOV>Q)3_`/_1TVT7=5ZK<&$CU[G.<_\`=:Y^RK_P-O\`T%;^L;ZJ,W%Z?4S]
M4Z<UCO2'+G.=N?\`UG^DW_/>K71ZV=.R*C=#&NSKZ++#H`YK#5AM?/\`I&NM
M]/\`X]:76OJTSJ60,JF[T+]H8^6[VN`^AI+'->W]Y:<L\8YH"1K'&)X3_6^1
MQH<KDER^0P%YI3'&/ZGST.+^LVG=>Z(:&WNRZBP^X`D%W_;7\YO_`+*P.J]?
MOZJQ^/AA]'3PX5WW1^EL+M&8M%;?\)?]%M/\Z_\`POHT[T`=&Z;18-^0_J5Q
M.T48C0P.=WKLR&E[OZ[6/WL70=)Z,:75Y>8UC;ZVEN-C5#]#C,=])M/[^1;_
M`-J,G\_^;_F_IQ<.##ZQ<S^AQ:?XL?\`NV<2YGF/U<N''']/V_5_C3_[B/K7
M^K_2!T[&-EC`S*O@V-!W;&C^:QVN^B[TV_3=^?:M9)5NI79-.%:_$J-V3MBI
MC8^D?:UQW0W:SZ;E4E*62=D^J1Z[-Z,8XL=1'I@.F_\`Z,\A]:NHC+Z@:&OB
MC$FH&8FP_P`^X?U?YG_MQ#ZGUVKJ.'1A58PQV8SVNKBP/]K&NK%>UO\`)<M3
MZL]!OKNNR.I41M;Z=3+=KBXN]]UQ^G_)9_VXKGUCZ7ZO3MN#BM=<+6.BMK6N
M@'W:^Q7QEPQGCQ`<7MU63B](E+YI.6<',9,>7,3P^[9EBX;F8P^6'[T6KT#+
MQ<?ZM9#LL_H*[+:W-&I<'?X-@_>L]1<_TAN-^T<1F4WU*#:&N8=1)]M/J?O-
M9;L]17<7H/6<EU>%=59C8GJ&VQQ+8:2-K[&[7.W7.9^CJ_T:L=?^K^6,T?LW
M&<['=4T#TRT;'L]GYSF_FBMZ?&6*,\D?<%YKE8/IA_A?OL<H9I8\4_:-<OPP
MX3'U9.I]/[GI:G7W.S>O753(-E6,P>`]N[_P2UZUOKE8UE&%B-T!L+X\&UMV
M_P#?U1ZCTSJ_VIG5:<5^ZXUWNK8`YU5[0T6,=7N_25N?7ZFYJE^R^N=>S!=U
M"LXM6T,<XC;M9,NKHI+K'^I9_I;4WT?J9&<1#%$WKZN/AX=EQ&3^D8QCF<F>
M0X37I]OBX_F>4^LA>UG1ZG"`<:V\#SNN/_?&5KJNF]%NZO\`XML3I>):RIV7
M2TV6/!<(=;]HR!#"/<[WL1_KK]4[NJ8F+=TIC?M6`TULQR0P64N`_0ML=[66
M5N8QU._V+DNGX_\`C`QJ7=,Z?CYV-383-;A76QI<=UAJR['/^SM>X[W_`&=W
M]19^27'.4OWI&7VNOBAP8X0WX(B/^*'-QNB8KOK-C]).S)#,YE%UK`6M>*G"
MW*V-<3]#T[*?["-ACJ'6OK,^[ISF-S\C*NR\>RW5C/2<?2<_1_\`-5>FVMJZ
M/ZN_4SJ72?K3@NN9ZN+C8SKK,ED"H7V!U/V:G<?6?Z6[?ZUC-]OT_8LZSH'U
MH^K'6SE]+PWY==;[#BW5-%K'56G<['R:6OKOK>S]]O\`GIJ]L]7^K?UXZEZ;
M.JY^#?90'.H8YXJC>-KW174W=NVK$^L5%MG6JND[@]^)1@])#FSM+FM:Z[;/
M\O)6]T_ZI=<^LO6F]8^M%(IQV%KC38&[[&UG=3AU4!UOV;":_P#27^J_U[_^
MN^JA=+^KW7\CZX5]0S>GVT8S\V[+?:\L(:UIL=BM.VQ[_P`VAGT4E-[_`!FW
MLK9TKIS-*VN?<6]@VIHJK_\`/JWOJ'BG&^J>`'"'WL=D/\S<]UX_Z%C5S'^,
M#HWUAZIUES\#`MOHJQ115:TL#2]Y<^P^^QKO9N:NNR!U'`9A8>"PFBFIM<M;
MNDL`K;6[_1\5_N?H_6L]7]#^D"G_TO0^K1^S\V?LD>V?M4^CPS^EQ^=_H_\`
MK*YIGV#[/7Z7V/U-(^T?;/LL_P`G[3^K[?ZZ\,25G#\I_GM_\E\FWZ34YCYX
M_P`QM_EOG^;]!^E^E;=PCT)])N[TIF?^"W>W[)^YZ7Z-::^54E!/YCO_`(38
MQ?(-O\'9^JDE\JI)J]^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?
M*J22GZJ27RJDDI^JDE\JI)*?_]G_[1;V4&AO=&]S:&]P(#,N,``X0DE-!"4`
M`````!``````````````````````.$))300Z``````#E````$`````$`````
M``MP<FEN=$]U='!U=`````4`````4'-T4V)O;VP!`````$EN=&5E;G5M````
M`$EN=&4`````0VQR;0````]P<FEN=%-I>'1E96Y":71B;V]L``````MP<FEN
M=&5R3F%M951%6%0````!```````/<')I;G10<F]O9E-E='5P3V)J8P````P`
M4`!R`&\`;P!F`"``4P!E`'0`=0!P```````*<')O;V93971U<`````$`````
M0FQT;F5N=6T````,8G5I;'1I;E!R;V]F````"7!R;V]F0TU92P`X0DE-!#L`
M`````BT````0`````0``````$G!R:6YT3W5T<'5T3W!T:6]N<P```!<`````
M0W!T;F)O;VP``````$-L8G)B;V]L``````!29W--8F]O;```````0W)N0V)O
M;VP``````$-N=$-B;V]L``````!,8FQS8F]O;```````3F=T=F)O;VP`````
M`$5M;$1B;V]L``````!);G1R8F]O;```````0F-K9T]B:F,````!````````
M4D="0P````,`````4F0@(&1O=6)`;^````````````!'<FX@9&]U8D!OX```
M`````````$)L("!D;W5B0&_@````````````0G)D5%5N=$8C4FQT````````
M````````0FQD(%5N=$8C4FQT````````````````4G-L=%5N=$8C4'AL0&*_
ME8`````````*=F5C=&]R1&%T86)O;VP!`````%!G4'-E;G5M`````%!G4',`
M````4&=00P````!,969T56YT1B-2;'0```````````````!4;W`@56YT1B-2
M;'0```````````````!38VP@56YT1B-0<F-`60```````````!!C<F]P5VAE
M;E!R:6YT:6YG8F]O;``````.8W)O<%)E8W1";W1T;VUL;VYG``````````QC
M<F]P4F5C=$QE9G1L;VYG``````````UC<F]P4F5C=%)I9VAT;&]N9P``````
M```+8W)O<%)E8W14;W!L;VYG```````X0DE-`^T``````!``E?RL``$``@"5
M_*P``0`".$))300F```````.`````````````#^````X0DE-!`T```````0`
M```>.$))3009```````$````'CA"24T#\P``````"0```````````0`X0DE-
M)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&````
M```!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4````!
M`"T````&```````!.$))30/X``````!P``#_________________________
M____`^@`````_____________________________P/H`````/__________
M__________________\#Z`````#_____________________________`^@`
M`#A"24T$`````````@``.$))300"```````"```X0DE-!#````````$!`#A"
M24T$+0``````!@`!`````SA"24T$"```````$`````$```)````"0``````X
M0DE-!!X```````0`````.$))300:``````-%````!@``````````````-0``
M`*8````(`&D`;0!A`&<`90`P`#``,0````$`````````````````````````
M`0``````````````I@```#4``````````````````````0``````````````
M```````````0`````0```````&YU;&P````"````!F)O=6YD<T]B:F,````!
M````````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG````
M``````!"=&]M;&]N9P```#4`````4F=H=&QO;F<```"F````!G-L:6-E<U9L
M3',````!3V)J8P````$```````5S;&EC90```!(````'<VQI8V5)1&QO;F<`
M````````!V=R;W5P241L;VYG``````````9O<FEG:6YE;G5M````#$53;&EC
M94]R:6=I;@````UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M````"D53;&EC
M951Y<&4`````26UG(`````9B;W5N9'-/8FIC`````0```````%)C=#$````$
M`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<`
M```U`````%)G:'1L;VYG````I@````-U<FQ415A4`````0```````&YU;&Q4
M15A4`````0```````$US9V5415A4`````0``````!F%L=%1A9U1%6%0````!
M```````.8V5L;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%6%0````!
M```````):&]R>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F
M875L=`````EV97)T06QI9VYE;G5M````#T53;&EC959E<G1!;&EG;@````=D
M969A=6QT````"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP
M90````!.;VYE````"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L
M;VYG``````````QB;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E
M=&QO;F<``````#A"24T$*```````#`````(_\````````#A"24T$%```````
M!`````,X0DE-!`P`````#><````!````H````#,```'@``!?H```#<L`&``!
M_]C_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)
M"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,
M#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`#,`H`,!(@`"
M$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!
M``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS
M`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S
M-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U
M5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1
M`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,'
M)C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6
MIK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/54DE0ZQU?'Z5C>K8-]
MKY%%(/N>[_OK&_X1Z,8RE(1B+)V"V<XPB92/#&.I*;/ZAA]/H.1EV"NL:">2
M?W6-^D]RP,GKF?E-%KKF=%Z>_6NVT;\FUO[U./KM;]'_`,FL3(SKK<@YF66Y
M&>?YMKA-..#QLJ/MLN;^:QWL9_A_5M55[WV6NNL<;+7_`$['G<X_%Q6EBY.,
M1<M9=]Q_@1E_TYN1G^(RD:C<8_N_*?\`JDH_^D\?_ACT6/D_5)SVMRKK\EY,
M"_.-KFF?^,BBO_MNM;]'3<:AS;,,NH')8QQ-;A_Q+B:O[=?O7GG^I7:?5"]]
MO1Q6XDC'L?4PG]T0Y@_L[]J9S>$PAQ1G(BZ,9&QJR<CS$<N3@EC@)5Q1G`<,
MO3W+MI))+/=522222E))))*4DDDDI22222E))))*4DDDDI__T/3\S+HPL6S*
MR';:JF[G'OY-;_*<[VM7GV;G9&=ENS+]+':,8-16P?0J9_5_/_X1;'UOZ@;<
MIG3V']'C@671WL=_--_ZW7^D_P"N,63B8M3J+<_-+F8&.=KMNC[K/S<6C_T;
M9_YVS3Y3$,>/W)?-/;OPGY8Q_ON-S^:6;+[,#Z,?S?N\4?FE+^KC14XS[6NL
M!;70P[;,BPD5M=&[T]`Y]U__``%#7V?U$G'$:8K;9?\`R[#Z0_LTU;G_`/;E
MJL=79D4/QFY3?2+J1972T;:J@\_T?';^]6W;]HL_G+;$3I?0L[J3P0UU&*?I
M9#Q$C_@&._G'?R_YI6.,"/'*51\_^Z_2:GM2,_:QP,I];&O^+\L8M;)HK9CX
MN76',JRO4'IO.XM=4=MFRR&[Z7_F[OH+L/JKCNHZ+2YXAUY=<1_7/L_\#V+G
MKZJ>L=6Q^F8`C`Q6^DQS3(]-I'VK(G_A7?H&/_POTUVS&M8T,8-K6@!H'``5
M/G,I]N$#\TCQD'YHP_R8DZ'P_"/>R9!1C$#&"/EE.H^[*/\`5XF2Y;JOUKRZ
M,ZZC"94ZJCV%U@<2;!_.1L>SVL=^C6SUSJ/[.Z=9>R/6=^CH!_TCOH_YG\[_
M`&%QS\$4]$Q\QP)LR<@M8\\^D&V?^?;6^JF<IAB?7D%@G@@#^]\Q9.?SSC^K
MQ2X91'N9)#]&'RQ'^$]OTS*?F=/Q\IX`?=6U[@WB2/=MF5:7+XV3G5?4ZG)P
M;/3NQI+_`&ATL:]S;&P\._-]ZKXGUKRZL#*^TO%V7N'V5Q:&C:YOO>_TQ_-X
M^W?_`"_YM,/*SD9F%5&9AP_I;KX\]CB,8R<0,L<<G'^B?3_TGL$ER?[<ZOT_
M!9=FVB[+RQNQZ'L:P5U-YR<CT@U^ZW\RG_U(JMO4_K13CTYUU[F47D"IQ97!
MGW,W4[-[6O;]#WI#DYG]*&_#$W\Y_JZ*E\0QQ_0R$UQ2``O''I[GJ>U<YK6E
MSB`T"23H``O/^L_XS+W7FGH5+'4[MC,NX.>;7=OLF+5M>YG^C>[^=_T*+];_
M`*R6Y'U5QJ6CTK^J/=3D!A,"NK^EAA^ELN_1U?\`%7J7^+7H]`Q[^MW,!N>]
MV/BN(^A57[+G5_\`'7[V/_D4UJ"43&1B=XFBVX3$XB4=8R'$/JYV!_C*ZQC9
M`_:U55V*UX;D;*W4W5#\Y_IV..[TYWOI>RMZ]*:YKVAS3+7"01W!7'?6WZE7
M]?ZJW+HRJ,.IV-Z%[W,+WN<'.+'[&NJ8[8Q^WWV(/UF^MU_0:Z.@]+B_/HIJ
M9?DO87!A(;70RK':?TV9D_395OV5_P#")JY[A)>99O6_K_\`5V['OZI<VYN0
M"]N.\4N8_8)LQW68U53\:_:[V.K?;3_QRO\`UP^N/4Z7=,/1LG[(S+PSF6%]
M;+"6V^G]FW>J';/3_2N]B2GODEYAU/ZR_7<86)G/=9@=/N8RNF\,IWWV;=QR
M+@YECJ/M&U]E%/H4U^E_I5U_U(ZSG=8Z)]HSR'Y%-UE!N:`WU!61MM=6WV,?
M[MK]GL24_P#_T=-M%W5>JW!A(]>YSG/_`'6N?LJ_\#;_`-!6_K&^JC-Q>GU,
M_5.G-8[TARYSG;G_`-9_I-_SWJUT>MG3LBHW0QKLZ^BRPZ`.:PU8;7S_`*1K
MK?3_`./6EUKZM,ZED#*IN]"_:&/EN]K@/H:2QS7M_>6G+/&.:`D:QQB>$_UO
MD<:'*Y)<OD,!>:4QQC^I\]#B_K-IW7NB&AM[LNHL/N`)!=_VU_.;_P"RL#JO
M7[^JL?CX8?1T\.%=]T?I;"[1F+16W_"7_1;3_.O_`,+Z-.]`'1NFT6#?D/ZE
M<3M%&(T,#G=Z[,AI>[^NUC][%T'2>C&EU>7F-8V^MI;C8U0_0XS'?2;3^_D6
M_P#:C)_/_F_YOZ<7#@P^L7,_H<6G^+'_`+MG$N9YC]7+AQQ_3]OU?XT_^XCZ
MU_J_T@=.QC98P,RKX-C0=VQH_FL=KOHN]-OTW?GVK625;J5V33A6OQ*C=D[8
MJ8V/I'VM<=T-VL^FY5)2EDG9/JD>NS>C&.+'41Z8#IO_`.C/(?6KJ(R^H&AK
MXHQ)J!F)L/\`/N']7^9_[<0^I]=JZCAT856,,=F,]KJXL#_:QKJQ7M;_`"7+
M4^K/0;Z[KLCJ5$;6^G4RW:XN+O?=<?I_R6?]N*Y]8^E^KT[;@XK77"UCHK:U
MKH!]VOL5\9<,9X\0'%[=5DXO2)2^:3EG!S&3'ES$\/NV98N&YF,/EA^]%J]`
MR\7'^K60[+/Z"NRVMS1J7!W^#8/WK/47/](;C?M'$9E-]2@VAKF'42?;3ZG[
MS66[/45W%Z#UG)=7A7568V)ZAML<2V&DC:^QNUSMUSF?HZO]&K'7_J_EC-'[
M-QG.QW5-`],M&Q[/9^<YOYHK>GQEBC/)'W!>:Y6#Z8?X7[['*&:6/%/VC7+\
M,.$Q]63J?3^YZ6IU]SLWKUU4R#95C,'@/;N_\$M>M;ZY6-91A8C=`;"^/!M;
M=O\`W]4>H],ZO]J9U6G%?NN-=[JV`.=5>T-%C'5[OTE;GU^IN:I?LOKG7LP7
M=0K.+5M#'.(V[63+JZ*2ZQ_J6?Z6U-]'ZF1G$0Q1-Z^KCX>'9<1D_I&,8YG)
MGD.$UZ?;XN/YGE/K(7M9T>IP@'&MO`\[KC_WQE:ZKIO1;NK_`.+;$Z7B6LJ=
METM-ECP7"'6_:,@0PCW.][$?ZZ_5.[JF)BW=*8W[5@--;,<D,%E+@/T+;'>U
MEE;F,=3O]BY+I^/_`(P,:EW3.GX^=C4V$S6X5UL:7'=8:LNQS_L[7N.]_P!G
M=_46?DEQSE+]Z1E]KKXH<&.$-^"(C_BAS<;HF*[ZS8_23LR0S.91=:P%K7BI
MPMRMC7$_0].RG^PC88ZAUKZS/NZ<YC<_(RKLO'LMU8STG'TG/T?_`#57IMK:
MNC^KOU,ZETGZTX+KF>KBXV,ZZS)9`J%]@=3]FIW'UG^ENW^M8S?;]/V+.LZ!
M]:/JQULY?2\-^776^PXMU31:QU5IW.Q\FEKZ[ZWL_?;_`)Z:O;/5_JW]>.I>
MFSJN?@WV4!SJ&.>*HWC:]T5U-W;MJQ/K%1;9UJKI.X/?B48/20YL[2YK6NNV
MS_+R5O=/^J77/K+UIO6/K12*<=A:XTV!N^QM9W4X=5`=;]FPFO\`TE_JO]>_
M_KOJH72_J]U_(^N%?4,WI]M&,_-NRWVO+"&M:;'8K3ML>_\`-H9]%)3>_P`9
MM[*V=*Z<S2MKGW%O8-J:*J__`#ZM[ZAXIQOJG@!PA]['9#_,W/=>/^A8U<Q_
MC`Z-]8>J=9<_`P+;Z*L4456M+`TO>7/L/OL:[V;FKKL@=1P&86'@L)HIJ;7+
M6[I+`*VUN_T?%?[GZ/UK/5_0_I`I_]+T/JT?L_-G[)'MG[5/H\,_I<?G?Z/_
M`*RN:9]@^SU^E]C]32/M'VS[+/\`)^T_J^W^NO#$E9P_*?Y[?_)?)M^DU.8^
M>/\`,;?Y;Y_F_0?I?I6W<(]"?2;N]*9G_@MWM^R?N>E^C6FOE5)03^8[_P"$
MV,7R#;_!V?JI)?*J2:O?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ2
M7RJDDI^JDE\JI)*?JI)?*J22G__9`#A"24T$(0``````50````$!````#P!!
M`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E`"``
M4`!H`&\`=`!O`',`:`!O`'``(`!#`%,`-@````$`.$))300&```````'``@`
M```!`0#_X0XI:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K
M970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_
M/B`\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K
M/2)!9&]B92!835`@0V]R92`U+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P,3(O,#(O
M,#8M,30Z-38Z,C<@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+R(@>&UL;G,Z9&,](FAT='`Z+R]P=7)L
M+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIP:&]T;W-H;W`](FAT='`Z
M+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B('AM;&YS.GAM<$U-/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=$5V=#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E179E
M;G0C(B!X;7`Z0W)E871O<E1O;VP](D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I(B!X;7`Z0W)E871E1&%T93TB,C`Q,RTP."TQ-50P-3HR-SHP."LP
M-3HS,"(@>&UP.DUO9&EF>41A=&4](C(P,3,M,#@M,354,#4Z,C<Z-3(K,#4Z
M,S`B('AM<#I-971A9&%T841A=&4](C(P,3,M,#@M,354,#4Z,C<Z-3(K,#4Z
M,S`B(&1C.F9O<FUA=#TB:6UA9V4O:G!E9R(@<&AO=&]S:&]P.D-O;&]R36]D
M93TB,R(@<&AO=&]S:&]P.DE#0U!R;V9I;&4](G-21T(@245#-C$Y-C8M,BXQ
M(B!X;7!-33I);G-T86YC94E$/2)X;7`N:6ED.D8W0D-!,C4T,T0P-44S,3$X
M,44X14(Y-CE#-3-"144T(B!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.C8W
M031",4$W,4(P-44S,3$X,44X14(Y-CE#-3-"144T(B!X;7!-33I/<FEG:6YA
M;$1O8W5M96YT240](GAM<"YD:60Z-C=!-$(Q03<Q0C`U13,Q,3@Q13A%0CDV
M.4,U,T)%130B/B`\>&UP34TZ2&ES=&]R>3X@/')D9CI397$^(#QR9&8Z;&D@
M<W1%=G0Z86-T:6]N/2)C<F5A=&5D(B!S=$5V=#II;G-T86YC94E$/2)X;7`N
M:6ED.C8W031",4$W,4(P-44S,3$X,44X14(Y-CE#-3-"144T(B!S=$5V=#IW
M:&5N/2(R,#$S+3`X+3$U5#`U.C(W.C`X*S`U.C,P(B!S=$5V=#IS;V9T=V%R
M94%G96YT/2)!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*2(O/B`\<F1F
M.FQI('-T179T.F%C=&EO;CTB8V]N=F5R=&5D(B!S=$5V=#IP87)A;65T97)S
M/2)F<F]M(&EM86=E+W!N9R!T;R!I;6%G92]J<&5G(B\^(#QR9&8Z;&D@<W1%
M=G0Z86-T:6]N/2)S879E9"(@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#I&
M-T)#03(U-#-$,#5%,S$Q.#%%.$5".38Y0S4S0D5%-"(@<W1%=G0Z=VAE;CTB
M,C`Q,RTP."TQ-50P-3HR-SHU,BLP-3HS,"(@<W1%=G0Z<V]F='=A<F5!9V5N
M=#TB061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RDB('-T179T.F-H86YG
M960](B\B+SX@/"]R9&8Z4V5Q/B`\+WAM<$U-.DAI<W1O<GD^(#PO<F1F.D1E
M<V-R:7!T:6]N/B`\+W)D9CI21$8^(#PO>#IX;7!M971A/B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(#P_>'!A8VME="!E;F0](G<B/S[_X@Q824-#7U!23T9)
M3$4``0$```Q(3&EN;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P
M35-&5`````!)14,@<U)'0@```````````````0``]M8``0````#3+4A0("``
M````````````````````````````````````````````````````````````
M`!%C<')T```!4````#-D97-C```!A````&QW='!T```!\````!1B:W!T```"
M!````!1R6%E:```"&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD
M```"5````'!D;61D```"Q````(AV=65D```#3````(9V:65W```#U````"1L
M=6UI```#^````!1M96%S```$#````"1T96-H```$,`````QR5%)#```$/```
M"`QG5%)#```$/```"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H
M8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2
M<U)'0B!)14,V,3DV-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N
M,0``````````````````````````````````````````````````````````
M````````6%E:(````````/-1``$````!%LQ865H@````````````````````
M`%A96B````````!OH@``./4```.06%E:(````````&*9``"WA0``&-I865H@
M````````)*````^$``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE
M8RYC:```````````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M``````````````````````````````````````````````````!D97-C````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(``````````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O
M;&]U<B!S<&%C92`M('-21T(`````````````````````````````9&5S8P``
M```````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V
M+3(N,0``````````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I
M;B!)14,V,3DV-BTR+C$``````````````````````````````````'9I97<`
M`````!.D_@`47RX`$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0
M````5Q_G;65A<P`````````!`````````````````````````H\````"<VEG
M(`````!#4E0@8W5R=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W
M`#L`0`!%`$H`3P!4`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`
MJ0"N`+(`MP"\`,$`Q@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?
M`24!*P$R`3@!/@%%`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!
MP0')`=$!V0'A`>D!\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$
M`HX"F`*B`JP"M@+!`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#
M?@.*`Y8#H@.N`[H#QP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:
M!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%
M]@8&!A8&)P8W!D@&609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T
M!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24)
M.@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB
M"SD+40MI"X`+F`NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-
M6@UT#8X-J0W##=X-^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S
M#\\/[!`)$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D42
M9!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T
M%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`8
M91B*&*\8U1CZ&2`911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR
M&]H<`APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?
M:1^4'[\?ZB`5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X
M(V8CE"/"(_`D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG
M>B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1
M+`4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PP
MI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'
M-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z
M[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D
M0*9`YT$I06I!K$'N0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&
M9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR
M3+I-`DU*39--W$XE3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3
M$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX
M6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@
M_&%/8:)A]6))8IQB\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_
M:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P
M*W"&<.!Q.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1
M>&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`
MJ($*@6N!S8(P@I*"](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDS
MB9F)_HIDBLJ+,(N6B_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2
M>I+CDTV3MI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INO
MG!R<B9SWG62=TIY`GJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BE
MJ:8:IHNF_:=NI^"H4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+
ML`"P=;#JL6"QUK)+LL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z
M.[JUNRZ[I[PAO)N]%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.
MQ4O%R,9&QL/'0<>_R#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0
M.="ZT3S1OM(_TL'31-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`
MW`7<BMT0W9;>'-ZBWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_G
MJ>@RZ+SI1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G
M]#3TPO50]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____
M[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!
M`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P/_P``1"``U`*8#`1$``A$!`Q$!_]T`!``5_\0!H@``
M``8"`P$`````````````!P@&!00)`PH"`0`+`0``!@,!`0$````````````&
M!00#!P((`0D`"@L0``(!`P0!`P,"`P,#`@8)=0$"`P01!1(&(0<3(@`(,11!
M,B,5"5%"%F$D,Q=2<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$5'-%1C='
M8RA55E<:LL+2XO)D@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI:G9W>'EZ
MA8:'B(F*E)66EYB9FJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;G
MZ.GJ]/7V]_CY^A$``@$#`@0$`P4$!`0&!@5M`0(#$00A$@4Q!@`B$T%1!S)A
M%'$(0H$CD152H6(6,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#
MDT9TPM+B\E5E=58WA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:F
MML;6YO9G=X>7I[?'U^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ
M>HJ:JKK*VNKZ_]H`#`,!``(1`Q$`/P#?X]^Z]U[W[KW2.W]V#LGJW:F6WSV'
MN?$;0VG@X/N,GG,U5+2T=.I.F.)+ZIJJLJ9+)#!"LD\\A"1HS$`FNR[)N_,>
MY6VS['M\MUN<S42.,58^I]`H&69B%498@"O1%S+S/R_R=LM[S%S1N\%CLMNN
MJ2:5@JKZ`>;,QPJ*"[L0JJ20.JD=Z?/CN+O.CRN2^.<.SOCU\?\`&UM1BLO\
MM/D0U/C:&OJ:>.1JBDZTV56R*<_F1X)%C@T5L@<**A*-SI]Y-;3[+<K<G2VT
M'/;76^<[R('39=LJ[*"11KNX4?I1Y!+504J4,HSUA/OOWD^>?<2"]N_:V.QY
M8]LX9&CEYDWK3&CLH-5L+5S^M+@Z5TRM6@E$#&G0-;;W[_+EK,Q&_P`A/E%W
M;\G]Q2MIK=T=D'M^AZK@G8A6;$;,VQC\7MS&8I3^D3)61J#<R$?057^R>_$-
MJPY(]NMHY>L1\,5K]$UX1Z//,SRN_KI*$_PUZ`NU\S_=8N;U?]<WW?W_`)NW
M-CWSWW[S3;U;@?"MH$CACB]`_BJ,G53JU+KSXZ_&YL)@]^?'^&GV919:CI\E
MMS>73^[,G0X?)T9D$D<D^/H\G5[2W-0RO&4FAKZ.J0D,K!7!MCAOO/7/OU=Y
MLW.SM=S1N5E@OH4:1&\P&9!-$PK56C=#P()'',?E?VN]JCM^W<Q^VD:6%O,B
MR076V7$B12+6H)1)&MKA"11EFBD'$$!A@U=,D\=-!'53+45*0QI/4)%X$GF5
M`))E@#R"$2N"VG40M[7/N.'*,[F-=*$F@K6@\A7%:>O4R1+(L4:RN&E"@$@4
MJ?,TS2O&E33K/[ITYU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_]#?X]^Z]T"O?W?O7GQNZWR_9?8^
M2:EQE#:CQ.(H_%+G=U9^HCD;';;V[1221_>Y6O:(VN5CAB5YI62*-W46\E<E
M;[S[O]KR_L-OJN'[G=JB.&,$:I96H=*+7YEB0J@LP!`'N7[E<K^U/*E]S;S5
M=Z+./MCC6AFN)F!T00(2-<CT/F%50SN5168:O_?7R;W7\B-XT_97>=+'F\/C
MY9JOJ'XYTN2K:;8V`H9RR4^X^PJN@DHLADH9XK&0Q-#DLZRF.)Z#&#]WH=R7
M[>[=R-M<G+_)LAANG`6^W0JIN)&'&*U5@RJ0>%0T5O74PFN/AY">Y/NYO/NA
MOD7-GN)`+BQB8MMFQK(ZVD*&H6>]9"CN"*:M)6>\(*H;:T^,LN]]\[O[)S--
MGM]9VHW!D,?118O"P/!2X_`[6P].H2EP.R]KXV*FV_L_`4<2A(Z3'T\*:1=R
M[EG,A[/LVU<OVDEELUDL$$CEY#4M)-(>,D\SDR3R,<EY&8^FD4`B+F'F+?.;
M+^'<N8]Q:ZN8HQ'$I"I#;Q+A8;6WC"PVL*C"QPH@\VU-5BE?9GT3=7D?R7^Q
M,R*[NOIZHJIY]N45)MWLC;]%([-387(96MR&#W-%11DZ8(<O+2TE0Z*`IG5W
M_4[$X>?>QV*T\+E+FF.-5OW:6UE8#,BHJR1%CYE`74$YTT'`#KHA]PCFF_-Q
M[@<C2SL^U1I!?0H3VQ/(SPSA!Y"0K$Y`QK#-Q8UOF]X8]=(.O>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[K_]'?9W3NC;^R-MYW>&Z\M28+;6V<579O.YBOD\=)CL7C:=ZJLJYF
M`9BL4,9(50SN;*H+$`K=NVZ^W>_L]KVVV:;<+B18XT459W8T51]I/G@<2:=%
MN\[QMG+^T[COF]7J6VTVD+RS2N:*D:*69C]@'`5)X`$D#K40^6GREW5\K>UY
M]\Y056.V-M]ZK&]5[*JO\QM_;SR+Y,OE*0-XIMU[I\23U\C:FBA\=(I\<1U=
M/_;+VYV[VUY:39[?2^\S@->7"\9):?V:-Q$,-2L8'Q-JE/<PIQ!]Z_>+>/>?
MG23F&[#Q<N6Q:/;K5N$,).99%X&XN*!YB:E5T0`Z4-0%VOM3=_8NX7P.T,'E
M-V;CGIZG+UT%'X0*''4ZWK,]N'+5\])B-NX&C1?W:ZOJ*:CA4!=8]*^QIN6Y
M[5L-@M[NEY':[>K!%+5[F/PQQ(H9Y9&\HXU=V.:<3U&VS[+OO-.Z-MNQ[?->
M[JRM*X6G8@^*:>1RL4$*CXIIGCB4"FK@.GC(8#8FW'%/E-[R;VRL9,=51=74
ML%3MFBG4VDC'8.YDI:'</C;TE\7CYZ74#IGD%B4D%]O5^-=MLXL[8Y#7A(F8
M>7^*PU:*OI-*KTXHO#I?=;9RWM3"*\YA.X7HPR;>JM;H?,?6W`5)Z<*V\+QU
MK21ADJ#(]=87(]29#N/9.1W`<7M;?N#ZYW]M;=E/BWR6%RFZ\35Y?:.XMO9[
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M/Q@2MY3J`B(,U^S_`+02^YTF\W-UN3V6SV:JOB+&)"\SFJQJ"R#"!G<UP-(I
MW=8T_>&^\+![(Q<MV=ALT6Y<Q;@[MX+RF)8[:(4>9F5)#W2,D<:Z0&.LU[#U
M(^"WS)S'R\Q?9M9F]BXK8U7U_F=MX^*FQ6?J\]'DJ7<.+K*Y*J62KQ6*:FDA
MGH9(PJJX8"]Q]/;?O%[56OM?<\OQ6F\R7D5]%*Q+QB,J8G5:`*[UJ&!KCIW[
MNWOO>^^%GS;/?\N0[=-MD\"!8YFF#K-&SAB6CCTD%&%`#7H^ON&.LD>O>_=>
MZ][]U[KWOW7NB8_-[YW]!_`7JR'LON[,U\E;GJNIP_7?76V*:+)[^[+W'2TZ
M5-1B-K8F6>EIUIL;3RI-D,A5S4^/QT#*T\RL\22;52QH.M$@=:R>[/\`A4%W
MM4[IFAV+\8>D,%@'F'V&`WQV9NS.;T:F)+)][5;>Q>$Q<55)$+D04U1&IO9G
M`N7?#'KU74>KW/Y8/\U;KO\`F-X'>F%&RZSJ7N[K"FQ&0WOUQ69F+<>+R&W,
MW)44F,WOL;<B46+ES6W*C)44M-4Q3TE-5XZIT1S(RRPRRMLNG[.K`UZM>]UZ
MWU[W[KW7O?NO=>]^Z]U[W[KW7__2V(_YP/R*GBBVO\7]LY!HERU-1;][5^VD
M_P`]AX*UALO:E5H?_,Y/*T,F1J8G4AXJ.`<K(?>8WW6^1$=]Q]Q-P@!,3-;6
M=1PD*_KS"HXHC")"#@R/YKUSI^_+[I21Q[/[0;3<D"=%O-QTGC$'/TMLU#PD
MD1IW4C*Q1\0QZJ,Z2Z3S?=>X,S"N:H-C=>;$Q)W7V]VSGX))=M=;;.A\DDU;
M.B:?XQNC*1P2)B<4C"6LF4LVF%'?WD]S?S?9\HV5HQM'O-]O9?!LK*,@2W4Y
MH`H_@A0D&:8X1305<@=81>WWM_N'N!N5^@W"/;N5]N@^HW/<I@3!86HJ2Y'^
MBW$@!%M;@ZI6%32-6/0@=YY@8KK[KK:G76"R?7'079='E]Y[0VED&U[Y[>P>
MT<RNVJ#N+O?-QI%)N#/;IRRSU&)P2_[A\%CUB,,.N1)21\FVOU.^;]N6_7D=
M_P`[;>R03S+_`+CV4DZ>*UCMT9KX4<*:5FN#^O<2EM345EZ%7N1>BPY9Y7V3
ME7;Y=K]M-VCDNK:W;-WN45M)X";GO$P`,\UQ+K>WM!_BMI"$,:$NLA!/K'K'
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MC38%^)?1--\<.@M@=5ZX*C-XO'297>61@`T93>NX)WRVYJP.I(FACR-2U/`W
M%Z:",6%K#"3W,YRDY]YUWOF2C+:22!(%/X((P$B7Y$J`S#^-FX]=,O93VYB]
MJO;7EGDW4K[A#$9+J0<)+J8F2=J^8#L40_[[1,#AT86NKJ/&459DLC5046/Q
M]+45U=6U4BPTU)1TD+U%555$SD)%!3P1L[L2`J@D^P/##+<2Q001EYG8*J@5
M+,30`#S))H!Z]2?<7$%I;SW=U,L=M$C.[L0%55!+,Q.`%`)).`!UJQ;IJ\I\
M[.\/E-WA5MD8NONJ>F][;PVK&/)&*7![3QN0HNI\%QY(H)-TY."MS58FI6=/
M(OX`]]&MMCM_9OD_VXY0B"?OS<]UMX9C@UDF=6O)/(D0H8[=#0T.D]<=-XEO
M/O&>X?O'[A3&4<L;-L-W<VXR-,5M&Z;=#Y@&XD$MU**@D:AT9C^31G*L;V^0
M>VJ*>"*HR6Q]D[AHON$>6G%70Y'<.,CGFBC>.26&)\C'K"LI*FP(O[`'WK;.
M,[1R1?RH2D=Y<1-3!TLL3D`Y`)TFF#U+/W#MPG','N=M,$BB67;K2=-52-2/
M/&"0""0-:UH1C%>EUT]_-"[PRGR(VKT[W;L?JC:>$GW]F>NM[9/#KNC'9#;^
M7Q_\6QD%>*G.YZHQU)CESM#%YFG3BEE+7!`/LFYI^[ORA;\B;CS5RCO&Y7-V
MME'=0))X++(C:'*TCC#%O#9M.D_&M,]"/D7[W_N%>>Z.S\B>X'+NS66WMN<M
MC=R1?4(\,J>)&'U33%%3QD747&(VK4'/0@8#^8QVSW1\BMR["Z+VSUG1]#[*
M%7F]X=P;^IMSS?P'KG:SRC=?8=6,?F<3CZ>CS+4TL>`I)526I"B:8K$)!&1W
MWL3RURER)M^]<X[AN#<YW>F."QMC$/$NI@/!MAJC=BT=5-RZU"5T*"Q74)]L
M^]+SIS][I;ORW[=[3M*>W&WZI;G<[Q;@^#8VY/U-ZVB6-%672RV<;`-)02.0
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M/\L3YG_!CY`Y?Y,?*5.J^K>LJ#H'>FW-[TL7:5'N3.QS25.U]RMD\V^(Q*[2
MH,!@EVY4U-54/DV6'2&`*ZF%G96``X]54$<>HG;7\^_Y2?(7N3*]/_RN_C.G
M9^*QE-DJ['[QW)M3<6]MZ;TP>&JEI:W?.(V)B<UM;$;&V#433Q+1U6=KVJJT
M2Q'P023)#[\$`%6/7M1/#HQ'\K/^==V3\G?D!+\0_EKUGMS8?<&2AW5#LC=6
MS\?G-L4=?N?85-5UN\NNM_[&W3D,GD=I[SH*#'U4U.\%5+!4&DFA>&&54,NF
M2@J#CK8-<'CT4K<O_"C#O3;/RQWIL.;J3J3._'7:?>6_=DT5;M+"=@9WNG=N
MR=IYS.;=P-%MJB3=D6W:S?N\LSC*>G@;[7[2(57D\3A-+6\,4K7/6M1KT`6[
MO^%&7\P78O9F1KM[_'OJ'8NW\!4BNS?06[MG]F[:WW2;=\8KA05F\=QY;$YB
MCW)58@ZJ>O?`1X^68JXI3";>]^&*<>M:C7K</_TS8+_0!_LPW\*R_P#=G_0[
M_IF_@GCI_P"/_P`"_N5_??\`A7B\WVO\7_A_[.GR>/S<:K<^VJ9ITY\^O__3
M.WW%E-W?)CY5=IY/`P5&8R^]NS,]C-N0DM,M+MO`96+9FUXFD"J?M5HZ.D1`
M!<RU(`%V/OJCRM!MGM[[:\N07K+%;6FWQO*>&J65#/*?MU,Y/HJ&IQUPGY[N
M][]V_>;G*[VR-I[V_P!WFC@&3I@AD%K;@G^$*L8`'%I!09Z-+\\L'@_C%U'U
M+\)]DU#&"OQG^F+Y`;FI;KDM^;EJ:ML;A8L@T2).]%25=#5U-/2W\:0T-"@3
MT7,<^S%W>>X?-',_NYN\8\1)/H=MB/P6T077(5J::BK(C/2I:28USB8OO(;?
MMWM#R1R5]W[EZ4^%+#^\]YG7X[R=F\.(/05**R22)'\(2&W73VYO=/1WQK[L
MZAZKH]P[%V'V1UYMO:&!FZ_K\G04=;38[!)A*&GIY\5DHC'-14U104L7G1)%
M1_&!("4%L-!SAS]RCS/S'-8[S>V&^W%U(+E49E+2>(Q(=3AB&)TD@D5[3GKH
MV?;SVH]P.1^3H-TY=VW=>5[2QA-D\B*RQPB)%4QN*%%9%76`P!H-0-,$<[S^
M;/2/QRQ3]!?"?9>R]V=PYRH.%QN+ZWPF+78FTLM)3O?)YZOQ$4./W1N#'0:I
M32)-(L*H\N0J*:"-]4P\G>T?-W/=P.=?=O=KNUY5A7Q'>ZD?ZB9`?@C5R6BC
M8T765!8D+`DCL*8\>XGW@/;[VLLV]M/N_P"P6%[SU<MX4<=C%']';2%3^I,\
M0"7$R"K&(,0@#/=2PQJU0=_EM?$W([R["K_EQVQDI]Z24F7S%9L;<64<UZ]A
M]AY&2:GW7VM2U,P5:[;>#D:7&8"I6-8ZR19JR`)3I1W%/OY[F0;7L<'MCRU;
MK:(T2+<1)V_36R4,-FP'PRR8FN4))C!2)ZR&;H#_`'5/92[WOFFY][.=KIK^
M2.>5K2>0Z_K;V0E;G<%8_%!"2UO9N%`D823QA8U@ZO@]X:]=&NJK?YK?R#/6
MG2-+U#MZO,&\N[Y*K#UIIIS'68KKC'")]X9#5'(LM.<T9H<5$Q%G%7,5YC)&
M1WW;.1QS!S?)S/?0:MJV@+(M157NFJ(%R*'PZ-,P\M"U^(5PW^^;[G'E+V^B
MY(VRYT[]S"6B?2:-'8I0W+X-5\6JVZGS$CD90TKL^,/R3^,G2GQ+[?ZLW!-O
M*3MSNC![Z@W%/C-CY.KPE)49';V2VOL?`)FDF^UGQ^(H)$EDF5519JN:_`]S
MI[A\@>X7-WN;RQS)9+:CEC:9K<Q![A%D(25)KB3PR*AG:H"Y)5$ZQ<]HO=?V
MB]O_`&5YXY-W*2_/.^_VUV)S':2-"K2026]I")0=)2-"&9P``\DGD.N?\GS+
M/B/DYG<-.RJ^XNDLS2,@;4KU6!W'M.O])XU:8YI2#_2_]??OO26PNO;VRNT'
M;!NZ-]@DBF7_``@=;^XS>FQ]W-QL)&`:ZY?E6GJT,]L^/L!;H%_YC^*V7C/F
M!VX=BY3'YN/+1X'+[MQU#<TV$[!J,-#3[BPE15`-3RUM3'24M74JA8P3U3I)
M:0,H%GL+<[M<>UW+/[XMWA,1D2%FXR6PD)BD`XA06=$)^)4!7MH>@%]ZNRV"
MT]\N=OZNWD5PLXADN8T^&*]:(+-$S<"[!8Y)`*Z'D96HP(!E>TL?U]T7_*^Z
M[H>K<A+DLO\`*_<6T*GL+=4]+'293<"18^MSVZ,#.$=Y:+$;<_N^,-#2!RB0
MF8GUS2EX_P"7)][YR^\1ODW,<`CM>6H)Q;0@ZDB[ECAD&*,\OB>.STJ6T4PJ
MTEGG&VY9]NON@\KV_)UR9KWG2ZMFO;@J%DF`1YKB$T)*QP>#]*D8)`7Q*]TC
MEC'?R?\`9N+VOTYW1W9E4A23.;MFP*U[QK]Q2[9ZYPJ5M;%%(>5I9,OF*IV4
M6#/$"?TBP#^]'NMQN/-7*?*-L25AM1)IKAI;J32I(]0B(!Z`_/J5/N-[#9[/
MR)S[[@7BJ'N;TPZZ96WL8@S`'^$R2R$CS*YX#JE_K#=^6Q>^.R.X\$T]-6;&
MZG^4_=E/-2:HY:5:'J_L#(4,T;(/V1'D-P4H!^@)'N=_?*2+9O9GFBRE-7-K
M:VBU\W+PH/V:&/Y=8K_=@AFYC^\?R-N,`(C%_?7[4\HA'<2G\B9$7\QT1S^0
M=LFBW=_,K^/IRJ)4Q;`ZZ[4W_"DH#"7-8W8J[6QM5S]9J:7=LDRM]0RW]\W9
M,*>NSR\>K&OYT)_FI=;?('NKY);.['[FZ3^&.!3JG8VR\ALWY%X?;F*R.2J,
M3C\55Y3&]:83<<>Y#DMR;VR]1'(31^8PTZR26B0-[TFF@'GULEA]G5:F'^5O
MR9RW\MWYA93MGY`]R]H'OGO/H3XK;0@[$["W-N>GPFT\3MS=W=/=U1MZ'(U4
MM+25>Y<'!B,-72"SM256CD$^]T&H8ZU4D&IZ$K^59W1\_OC%MCM+L7X=?`Z3
MY-X?M7.XK;^=[1K-O[FKHL,W7]/4Q2[#P=?M[,8P)24N0S4E76(ZF]5*MRWC
M4)YM)IJ/7AJ\AT(7QEZ7^;NU_P"8S7_S`/DS\5.UNF]J;=R/R=^4O:&YLSM7
M^";!VUD:;I'LO)T6`HZVLRU76FEK\]5TE%21R>2>>_K))8^]$KIT@];H:U/0
M8?\`"?OJD=R?S%]E[MW3CHLTG4/6/87>F6-?"M5%3[XSM3BMJ[?R3>0$+7T6
M9WM6U4#_`*DGA#CE;C;GMZTHSTCOYQF=F^17\U_N?9NWK5,C[OZ3^,N(CC2[
M'(18W;F$S6K2`TC0[AWK6C\D"*WX]^3"CKS9/6_Q_<'`?Z./]%WVZ_W6_N1_
M<'[31Z/X!_`?[N_;Z-7Z?X=Z;7^GY]LUS7ISK__4O+_EZ=84&UNR]H[CWA%'
M'F]V?)#M7K&GBKU,;P5?0O7^?SGV<4KNH2LRF^,G/5&,#7*,/'?A;>\Z_?+F
M*;<M@W*QVMB;.UV"SNR5\QN5S%'J(_A2W14KP7QV]>N6_P!V+DZWV3FS9=TW
MY`-QON:MPL%#^3;1933!02?CDNY'ET_$WTRUX$=&*_F0?!'M[N_L?"=S]*TF
M*W16MM2BVIN[9M?FJ3!98-A*S(5>'SNWZS)F'$UD4E-DI(*FEEF@D#QQR1L^
MIU4"^PGO+ROR?L-YRGS;)+;P_4M-#.L9D3]155XY52KJ:H&1PK"A8,!0$RA]
MZO[N7._N%S5M_/O($,-Y<_1);7-J\JPR?I.[130O)2-@5D9)(V9&!"LA:K`5
MWX_^7U\H,/M^1^V-S;9^/G58G=LG4[X[0JZ_&2R2^2:>DP_76RLGD(<_FJQ(
MW:*DU0/4L#:Y]SG/[W^W=U?`<M;=<;YS)I[!;VBJP`H`SW5PBF.-:@%Z,%'I
MUB[:_=C]W[';&/.F[VG+')NK]1KO<&>,DU)6*QM9'$TK`$K'5"Y]>C>_%3X2
M[<[',E-M+"[GVW\;G1<=OGM?>--'@NWOE)2P2(U9L/9F+QNF#J'XXSUT!&2C
MHG7)[CC44\]1)'Y3'%ON3[N[AL>F3=+NWN.?`==O9P$R66T$CMN)V?-[N@4_
MI&0&*U)UHBMIU3M[+_=_VCF57BV/;[RU]KS^G=[E=*(=RW]007M+2./&V[(S
MBDRQ$3WB@1R2."QCOHQF,QV%QN/P^'H*/%XG$T-)C,7C,?30T=!CL=001TM%
M04-)3I'!2T='31+'%&BJB(H4```>\,[BXGNYY[JZF>2YE<N[L2S,S$EF9C4E
MF))))J2:GKHY:6EK86MM8V-LD-E#&L<<:*%1$0!41%4`*JJ`JJ`````*=9JN
MKI:"EJ:ZMJ(*.BHZ>:KJZNIE2"FI:6GC::HJ*B>5ECA@@B0L[L0JJ"2;>Z1Q
MR321PQ(6E9@%`%2230``9))P`.)Z<FFAMX9;BXE5((U+,S$!5514LQ.```22
M<`9/6K1DLS5_S'/GS24=%45LNP<IFY,1C9::26"7!]$=>S5%37Y2!W,\>.R&
M\)Y7F1@?^!65B`YC4#HQ;VD?L/[*RRRQH-[CA#N"`1)N-R`%0\"ZP`!2/X(6
M_B)ZX[7=_/\`>H^\I#!!+(W+4MP8D*D@P[19%F>13D(]TQ+`_P"_+A*?"!U;
M)NK^5I\1<=MG<N2QNU=Y1Y"AP.:K,<7[&WA-%%6T^.J9J-VBDR;"98:A%.E]
M2M:S`@D'&G;OO&>Y\^X6$%QN5J8'FC5J6L`)4L`V0F*BN1P\J=9I;S]SOV1M
M-IW:[M-FOQ<QVTKI6^N2`ZHQ4T,F0&`-#4'@:CK78Z,[ZW%T/ND]F;/JJ"/=
MJ;'W=M?'U]:CM2X>JW9C(L>^X5I$736U6#DA%13T[?M23J@>Z`JV=/./)=CS
MGMHY?W2-SMGUD$S*O&187+>%J_")`=+,,A2:9H1RX]NO<K=/;C>#S;L4L0WO
M]W7-NCO73$US&$,VD?&T)&M$/:SA=55J"<+?'P@W9U[\)JKY.;]&<7LS*[VV
M]NG*X7)SU4M;M_J_<]5/C:JOW7%*GEJ=Z9S/9BER]=+*Q:EB;P&TGE'N+-G]
MW]MWSW<B]O=D\'^KT5I+"DB`!9;N%0X6$CA!'&CP1@8<C7\.GJ=>8?N][URQ
M]WZ;W<YE^H_K;-N$%Q)%(6+0[?<,8V>X!%6NI9I8[F9F-8U/AGNU]!9AZ_.]
MM?#'([*P4=?N++?&#N5^Q:G#T"2UU?!U!VM@,GC<IF:/%PK+65%#L_?5/+)6
M&)&%/25OE8!58@27<-ERQ[L0;M>,D%MS%M7TH=J*IOK.1&1&<T4-/;E0FHC4
MZ:1D@=`ZQN=QYV]A+K8-N26ZO>4-^-ZT25=QMFXPR))*L8!=EMKL,9=(.B.7
M610$]+CK/YZKUI\.MU_%W:VVF.\-V5N\:"DW_2YFAEH:7`[^KII\R1@X?+FZ
MO<\-%634=,D2^$ZHY2X9#&Q/S#[+GF#W3VWW$W'<!^ZK9(&:V9&#&2V4"/\`
M4-(UA+*KL2=6&6E#J`@Y2^\D.4O8O>?9_9MI)WV]DND6]65"BPWCEI?T165K
M@(SQ(%&DU5]0*Z"=[X"_`3,Y/ICO+<7<6'K]F2_(+IW=G2&S\!E*(Q9W;_7&
M],//09S=&4P]6D=1C,EGJAJ=J2EE,<Z4=&C2*AFTK`GWDO<S;.89K#DO8;U+
MFRM)S/<S(=4;W`!5(T8&CK"I8LPJID<A2=%3E;]S+V4WKE"#=/<OFO;9++<K
M^U%M8V\@*RQ6A(>2:5&`:)[AE0(C4<0Q@N!XFD:B6SMT_)7^4A\Q<3E<Y@:'
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M:.CADBR*Q0HTD!U^_%-1K7KP.*#H5%C^>O5G\I[Y>_)/YJ]]?(?)XOY`;1V%
M\=/CMTYWAN_/UN2DHNR>P-O+NWN#<6U=P0IE-OY+<.`@G@P--*Z5$>+2JJ)(
M$CJH;:QK``ZWG2:]&B_X3";$Q=OF5W]5LD5+C7ZXZDH<K)^W21TF+QF8[!W7
MJD8!56E_C.-,A!LNGGWJ0\!UY1Q/53O\ONH;Y?\`\Y?J[>$\XRC;T^5';?R2
MRIE`G4X#953O/L'#M4ZU,9A\M)B8EOP25`Y('NS80_9UH9;K=MIOF/#)WED^
MIYMAUBXBEWG1;`H\_#DC+DI\_4Y)L=+4S8@T*01T-&86FJ(%J'K::DJ*&>2/
M371*K-,5ZO7K_]7;*[\'Q:/6G9PU]B)D3\G8!M1^E8A+VI'\M_X=BQ5/TO&\
MT(FW>&\AR:U31XLM_$!.PC\Q$_<E_P"N-_6#E_%B8/ZO'QOKS2S_`'+K>GUQ
M`-(.'A%`9?[#0-6CK%'W%'L\>5>;0K;D+O\`K=_BYVL`[@.9/"36=K#$`W5-
M7C!R(=7U.H@:SUUAL+\YH\%2S93LGO&LI1%&S8U>DOAIC>R6IM(/AJLVWR!R
MNQTR1CX:5<>P#\^._'O=U=^S[7DB6^P;.LM3W_7[ZUK7U$?[M2XT5\C)P_%Y
M]-6-A]X==NADO.:^87@I_9C:>5TOM/HTIWJ2TUT_$(>.=-<=!YM]/CX-_8V3
MY&U/<;;LD+6H_D)1548I"M20/XKDI:^3%Y':\U38G^[=)2[2C.H5>M;-[.KX
M\[_N:=>14VK]V#\6V,O=C\"A0ZS`?\I3O>G!BH:CH,[8OMB.9+1O=*7?3O1K
MV[TC#3W?Z(Y<QO;EL_XC''MRY$VH4/5M%#]E]E1_PW[7^'?:T_V'V/B^R^R\
M2?:_9_;_`+'VO@T^/1Z-%K<>\:IO%\67Q]7CZCJU5U:JYU5S6O&N:\>LT[?Z
M?Z>#Z31]+H71HIHT4&G33&FE--,4I3'4KVWT]U@JOMOMJC[WP?9^"7[O[KQ_
M;?;>-O/]QY?VO!XKZ]7ITWOQ[O'XGB)X5?%J*4XU\J4S6O"G3<WA>%+X^GP-
M)U:J:=-,ZJXI3C7%./29P7]Q?NC_`'9_NE][]L;_`,"_@_W7V>J/5?\`A_[O
MVVO1?^S>W^'LPO/WQX?^[#ZGPM7^B:Z:L_Q8KQ^?'HHV[^KGC?[J/HOJ-'^@
M^%JTX_@SIK3Y<.E6^C0WDT^/2VO7;1HL=6K5QIM];\6]EHK44X]'3:=)U4TT
MS7A3H/A_HG].G_1Y^I=-O[M_KU#1IM_:UVM;F_L[/]9,U^NX?\-Z#`_J7BG[
MKK7']AQ_XOI:9/\`AGV%5_&?L/X7X_\`+?XG]O\`8>+4O_`K[K_)_'JM^OB]
MO93;_4>-']+K^HKVZ*ZJ_*F:_9T?WGTGTTWU_A_1T[O$TZ*?TM7;3[>F3"?W
M(^YG_NW_`'5^\^V_RK^"?PC[G[/R#_/_`&'[OVWEM^KTZO\`'VKN_P![^&GU
M_P!3X6K'B:Z:J>6K%:>F:=%^W_U?\:3]U?1^/H[O"\/5IKYZ,Z:^N*]!WA?]
MEO\`[V?[]W_0C_?G[DV_@O\`</\`O9]YJY_X`_[F/N=?U_MW]GMW_7S]V_X]
M^]_W/I_T3ZCP=/\`MNRG\N@OM_\`K5?OG_=7_5_^L.O_`$+Z/ZC5_M/U=5?S
MZ&[V$>I!Z!/NC_9<OX;C?]F(_P!"?\'\LW\'_P!-']Q?X;Y_VON/X;_?C_)?
M+^C7XN?TW_'O8KY=>^WI2[,_T1?W#7_1Y_HX_P!&'VM9I_N9_=C^X?V7C/W^
MG^!_[][[7Q?Y[^QI_5Q[U]O'KW2PP/\``?X/C_[K_P`(_N_X!_"OX#]G_!_M
M=3:?X?\`P_\`R+P:KV\?IO?W[KW1;L-_LD?^D;_?O_[*O_I<_B)O_!O]$G^D
M;^+^?G_@%_OYOXC]S_T]U_X^]YZT*>71A-U?W/\`X8G]]_[M_P`&^\@\?]ZO
MX7_#/O[2?;:/XO\`Y+]Y;5X[>OZV_/O76^HFV?[A?PNO_N=_=#^"^>;^*?W9
M_@W\+^X^WC^X^_\`X7_DGG^UTZ_)ZO':_%O?NO=,FV?]#W\5@_N;_HU_C?V\
M_P!M_=G^Z_\`%?M="_<^#^%?Y7]OX[:]/IM:_OW7NIM/_HQ_OY7_`&G]Q_\`
I29_#X_XG]O\`P+^^W\,T4GC^]\?^YO[3Q?;_`*_3H\7XT>_=:QU__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
